Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel Therapeutics in Haemato-Oncology – Hope or Hype?

Novel Therapeutics in Haemato-Oncology – Hope or Hype? editorial DOI 10.1007/s12254-009-0104-z Printed in Austria # Springer-Verlag 2009 genicity of cancer cells might produce collateral damage The past decade has seen a quantum leap in our level of in normal cells which share these properties. Despite this, understanding of the malignant process and anticancer there has been an extreme hype regarding the low toxicity drug development. In cancer medicine diagnostic innova- of targeted drugs. Indeed, some have turned out to be tions, novel drugs and therapeutic concepts have often quite nontoxic despite being extremely effective. A most primarily been developed for haematological malignan- notable example for such a drug is imatinib. This is al- cies. The 15th International Oncology Meeting (IOM) held most certain because this drug targets a specific mutation in Salzburg, Austria, from November 27–30, 2008 aimed highly specific for chronic myeloid leukaemia. Unfortu- at presenting an update on the most recent therapeutic nately, this favourable toxicity profile has not been shared achievements in the management of haematological neo- by other agents bearing the label of targeted drugs. plasias. The catchphrase of the past few years has At 15th IOM in Salzburg current treatment strate- been ‘‘targeted cancer therapy’’. Progress in this field of gies for http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Novel Therapeutics in Haemato-Oncology – Hope or Hype?

Novel Therapeutics in Haemato-Oncology – Hope or Hype?

Abstract

editorial DOI 10.1007/s12254-009-0104-z Printed in Austria # Springer-Verlag 2009 genicity of cancer cells might produce collateral damage The past decade has seen a quantum leap in our level of in normal cells which share these properties. Despite this, understanding of the malignant process and anticancer there has been an extreme hype regarding the low toxicity drug development. In cancer medicine diagnostic innova- of targeted drugs. Indeed, some have turned out to be tions, novel drugs...
Loading next page...
 
/lp/springer-journals/novel-therapeutics-in-haemato-oncology-hope-or-hype-7UroheR64r
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0104-z
Publisher site
See Article on Publisher Site

Abstract

editorial DOI 10.1007/s12254-009-0104-z Printed in Austria # Springer-Verlag 2009 genicity of cancer cells might produce collateral damage The past decade has seen a quantum leap in our level of in normal cells which share these properties. Despite this, understanding of the malignant process and anticancer there has been an extreme hype regarding the low toxicity drug development. In cancer medicine diagnostic innova- of targeted drugs. Indeed, some have turned out to be tions, novel drugs and therapeutic concepts have often quite nontoxic despite being extremely effective. A most primarily been developed for haematological malignan- notable example for such a drug is imatinib. This is al- cies. The 15th International Oncology Meeting (IOM) held most certain because this drug targets a specific mutation in Salzburg, Austria, from November 27–30, 2008 aimed highly specific for chronic myeloid leukaemia. Unfortu- at presenting an update on the most recent therapeutic nately, this favourable toxicity profile has not been shared achievements in the management of haematological neo- by other agents bearing the label of targeted drugs. plasias. The catchphrase of the past few years has At 15th IOM in Salzburg current treatment strate- been ‘‘targeted cancer therapy’’. Progress in this field of gies for

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jan 1, 2009

There are no references for this article.